Ewing Sarcoma | CHOP Research Institute

Ewing Sarcoma

This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.

Published on
Nov 30, 2022
The Emerging Innovators at CHOP Research Institute cover a variety of scientific disciplines.

The purpose of the Phase 2 portion of this study is to evaluate the safety and efficacy of the study drug called palbociclib when given in combination with two other drugs (temozolomide and irinotecan) in patients with Ewing sarcoma.

This study is looking to recruit CHOP patients 5-30 years old with suspected/ confirmed bone sarcomas. The study is looking to evaluate a new MRI technique to evaluate bones and any mass in them.

Published on
Jul 22, 2020
Dr. Patrick Grohar, director for Translational Research with the Center for Childhood Cancer Research, discusses development of a treatment for Ewing sarcoma.
Published on
Jan 31, 2020
MOMS2 study findings show benefits of prenatal surgery for spina bifida continue to childhood. This and more In the News.
Published on
Jan 17, 2020
In this week’s news roundup, our researchers approach challenges in children’s health research from a new lens.
weberk [at] chop.edu